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Introduction: Cytokines produced by B cells are believed to play important roles in autoimmune diseases. CD22
targeting by epratuzumab has been demonstrated to inhibit phosphorylation of B cell receptor (BCR) downstream
signaling in B cells. It has been shown that other sialoadhesin molecules related to CD22 have immunoregulatory
functions; therefore, in the present study, we addressed the role of epratuzumab on the production of key cytokines
by B cells of patients with systemic lupus erythematosus (SLE) and of healthy donors (HD).
Methods: Peripheral blood B cells were purified and activated by BCR with or without Toll-like receptor 9 (TLR9)
stimulation in the presence or absence of epratuzumab. Cytokine production by B cells (interleukin [IL]-6, tumor necrosis
factor [TNF]-α and IL-10) in the supernatant and the induction of IL-10+ B cells from patients with SLE and HD
were analyzed.
Results: The secretion of the proinflammatory cytokines TNF-α and IL-6 by anti-BCR and BCR- and/or TLR9-activated B
cells from HD and patients with SLE was inhibited by epratuzumab. In contrast, the production of IL-10 by B cells was not
affected by epratuzumab under either stimulation condition. Consistently, the induction of IL-10–producing B
cells in culture was not affected by epratuzumab.
Conclusions: Epratuzumab, by targeting CD22, was able to inhibit the production of the proinflammatory cytokines IL-6
and TNF-α by B cells, in contrast to IL-10, in vitro. These data suggest that targeting CD22 alters the balance
between proinflammatory cytokines (TNF-α, IL-6) and the regulatory cytokine IL-10 as another B cell effector mechanism.Introduction
Systemic lupus erythematosus (SLE) is a heterogeneous
autoimmune disease with a breakdown of self-tolerance
that leads to various immune abnormalities, including
the production of autoantibodies to double-stranded
DNA and other nuclear antigens, deposition of immune
complexes in various organs, and B cell disturbances
suggesting a key role for B cells in the pathogenesis of
this disease [1, 2].* Correspondence: thomas.doerner@charite.de
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any medium, provided the original work is pr
(http://creativecommons.org/publicdomain/zeroEpratuzumab, a humanized immunoglobulin G1 (IgG1)
monoclonal antibody (mAb) that targets the B cell surface
molecule CD22, is currently being tested in clinical trials
for the treatment of SLE, and it has been shown to modu-
late the activation of B cells. In this context, in vitro
mechanism-of-action studies have shown that epratuzumab
binding to CD22 on B cells leads to rapid internaliza-
tion of the antibody–CD22 complex [3], phosphorylation of
immunoreceptor tyrosine–based inhibitory motifs on the
CD22 intracellular tail [3], diminished proliferation of iso-
lated B cells from patients with SLE [4], and modification
of migration of B cells [5]. Recently, we demonstrated that
this anti-CD22 antibody is able to inhibit B cell receptor
(BCR) signaling in human B cells [6]. However, to date,article distributed under the terms of the Creative Commons Attribution
by/4.0), which permits unrestricted use, distribution, and reproduction in
operly credited. The Creative Commons Public Domain Dedication waiver
/1.0/) applies to the data made available in this article, unless otherwise credited.
Fleischer et al. Arthritis Research & Therapy  (2015) 17:185 Page 2 of 7whether other B cell functions, such as cytokine produc-
tion, can also be modulated by epratuzumab has not been
reported.
CD22 exclusively expressed by B cells is a member of the
sialic acid–binding immunoglobulin-type lectin (Siglec)
family, proteins known to modulate a wide range of im-
mune functions on dendritic cells (DCs), macrophages and,
in the case of CD22 (Siglec-2), on B cells [7]. In this regard,
cis signaling of certain Siglec family members is known to
regulate the balance of proinflammatory cytokines and the
regulatory cytokine interleukin (IL)-10 in DCs and macro-
phages [7]. Because cytokines produced by B cells following
BCR and/or Toll-like receptor (TLR) stimulation have been
described as playing an important role in autoimmune dis-
eases [8], and because epratuzumab is able to partially in-
hibit BCR responses [6], in the present study we analyzed
whether the antibody also has the capacity to modulate
in vitro the cytokine production (IL-6, tumor necrosis fac-
tor [TNF]-α and IL-10) by B cells from patients with SLE
compared with healthy donors (HD) upon BCR cross-
linking alone or in combination with TLR9 stimulation.
The latter appears to be involved in autoimmune B cell
activation in a T cell–independent manner, allowing us to
mimic autoimmune B cell–intrinsic TLR signaling.Methods
Patients and controls
In the studies investigating cytokine production, peripheral
blood was collected from 13 patients with SLE (12 females
and 1 male) with a mean age of 30.6 ± 8.8 years and with a
median Systemic Lupus Erythematosus Disease Activity
Index (SLEDAI) score of 6 (range: 4–15) and 9 HD
(8 females and 1 male) with a mean age of 33.4 ± 11.5
years. For the activation analysis and IL-10 production
of B cells using flow cytometry (FC), peripheral blood
was collected from six female patients with SLE with a
mean age of 38.8 ± 12.9 years and a median SLEDAI
score of 6 (range: 5–18). Ten HD (8 females and 2
males) with a mean age of 32.9 ± 11.1 years served as
controls. The study was approved by the ethics com-
mittee at the Charité-Universitätsmedizin Berlin, and
written consent was obtained from all donors. All patients
met the revised American College of Rheumatology classifi-
cation criteria for SLE [9]. Disease activity was assessed
using the Safety of Estrogens in Lupus Erythematosus
National Assessment–SLEDAI score [10].Peripheral blood mononuclear cells and B cell purification
Peripheral blood mononuclear cells (PBMCs) were isolated
by density gradient centrifugation as previously de-
scribed [11]. B cells were negatively purified magnetically
(B Cell Isolation Kit II; Miltenyi Biotec, Bergisch Gladbach,
Germany) according to the manufacturer’s instructions. Bcells were analyzed regarding their purity to minimize the
contamination by other cytokine-producing cells.
B cell purity
A total of 100,000 purified B cells were stained with anti-
bodies against CD14-PacB (M5E2), CD3-PacB (UCHT1)
and CD19 PE-Cy7 (SJ25C1) (all from BD Biosciences, San
Jose, CA, USA) for 15 minutes at 4 °C. Afterward,
4′,6-diamidino-2-phenylindole (DAPI) was added to
the stained cells (dead cell staining) and analyzed
by FC using a FACSCanto II flow cytometer (BD Bio-
sciences). Data were evaluated using FlowJo software
(version 7; Tree Star, Ashland, OR, USA). The total
B cell (CD3−CD14−DAPI−CD19+) purity was 98.5 ±
2.2 % in almost all samples (mean ± standard deviation),
with the exception of two cases with 8.2 % and 5.6 % non–
B cells (CD3+ cells, CD14+ cells or cell debris). These two
samples were outliers but did not show any results substan-
tially different from the remaining samples. Additional ana-
lyses also did not show any relationship between cytokine
levels in the supernatants of TNF-α, IL-6 or IL-10 and the
frequency of non-B cells of these samples, including any re-
lationship of the impact of epratuzumab and the frequency
of non-B cells after purification (data not shown).
B cell in vitro stimulation
Cells were resuspended in RPMI 1640 GlutaMAX
medium (Life Technologies, Darmstadt, Germany) supple-
mented with 10 % fetal calf serum (Lonza, Cologne,
Germany), 5 % penicillin-streptomycin and 0.05 mM
2-mercaptoethanol (Gibco; Life Technologies) at 1.1 × 106
purified B cells/ml or 1.1 × 107 PBMCs/ml. Cells (90 μl)
were seeded, pretreated with 10 μg/ml F(ab′)2 epratuzumab
(provided by UCB Celltech, Slough, UK) for 15 minutes
and stimulated with 2.5 μg/ml CpG 2006 (TIB MOLBIOL
Syntheselabor, Berlin, Germany) and/or 2 μg/ml F(ab′)2
anti-human IgM/IgG (anti-BCR; Jackson ImmunoResearch,
Suffolk, UK) for 48 hours at 37 °C in 5 % CO2 [4]. Because
the anti-BCR can potentially bind to the crystallizable frag-
ment (Fc) region of the whole anti-CD22 antibody epratu-
zumab, and because Sieger et al. [6] could show that
epratuzumab and F(ab′)2 epratuzumab have the same effect
on BCR signaling, the F(ab′)2 fragment of epratuzumab
was used to study the effect of the anti-CD22 antibody on
the cytokines production after TLR9 and/or BCR activa-
tion. For the cytokine analysis, supernatants from the B cell
in vitro cultures were harvested and frozen at −70 °C. For
the intracellular IL-10 staining, PBMCs stimulated in vitro
were used. Unstimulated B cells were used as a negative
control.
Interleukin-10 staining for flow cytometry
Intracellular staining for IL-10 was performed on PBMCs
after 2 days of in vitro culture. PBMCs were restimulated
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and 700 ng/ml ionomycin, including 2 hours with 2 μg/ml
brefeldin A (all from Sigma-Aldrich, Munich, Germany).
PBMCs were stained first on ice for 10 minutes with anti-
bodies against CD14-PacB (M5E2), CD3-PacB (UCHT1),
CD27-FITC (L128), CD38-PerCP/Cy5.5 (HIT2) and CD20-
PacO (H147) (all from BD Biosciences). After a washing
step, PBMCs were incubated with 400 μl of BD FACS Per-
meabilizing Solution 2 (BD Biosciences) for 10 minutes at
room temperature (RT). After another washing step,
PBMCs were stained with anti-IL10-APC antibodies (JES3-
9D7; Miltenyi Biotec) for 10 minutes at RT. Stained cells
were analyzed by FC using a FACSCanto™ II flow cytometer
and analyzed using FlowJo software. Unstimulated PBMCs
with brefeldin A treatment were used as a control.
Cytokine assay
Frozen supernatants of purified B cells stimulated in vitro
were assessed for the cytokine concentrations of IL-1β,
IL-4, lL-6, IL-10, IL-17A, IL-17F, IL-22, IL-23, IL-25,
IL-31, IL-33, interferon-γ, sCD40L and TNF-α by using
the Bio-Plex Pro™ Human Th17 Cytokine Panel (Bio-Rad
Laboratories, Hercules, CA, USA) according to the manu-
facturer’s instructions. The assay sensitivity depends on the
particular cytokines analyzed, ranging from 0.02 pg/ml for
IL-1β to 2.13 pg/ml for IL-21. A significant and spe-
cific induction after anti-BCR and CpG stimulation
above 20 pg/ml was observed only for the cytokines
IL-6, TNF-α and IL-10. Therefore, the other cytokines
were not considered in further analyses.
Statistical analysis
The statistical analysis was performed with GraphPad
Prism 5 software (GraphPad Software, San Diego, CA,
USA). To compare HD and SLE groups, nonparametric
Mann–Whitney U tests were applied. In comparative
analyses of data with or without F(ab′)2 epratuzumab
incubation, we applied the Wilcoxon signed-rank test
test. P values <0.05 were considered to be statistically
significant.
Results
Epratuzumab modulates the production of
proinflammatory cytokines by activated B cells
In initial studies, we evaluated whether the production
of proinflammatory cytokines such as TNF-α and IL-6
by purified peripheral B cells from patients with SLE
and HD differed upon activation by BCR alone or
combined with TLR9 activation. The results showed
that the most striking TNF-α induction in both HD
and SLE B cells was for simultaneous activation of
BCR and TLR9 in comparison with BCR activation
alone (Fig. 1a). Notably, and consistent with previous
data that epratuzumab partially inhibits BCR signaling [6],B cells pretreated with F(ab′)2 epratuzumab secreted
significantly less TNF-α upon BCR cross-linking
(HD: 11.7 ± 3.1 pg/ml, pretreated with F(ab′)2 epratu-
zumab 8.1 ± 3.8 pg/ml; p < 0.05; patients with SLE: 12 ±
9.3 pg/ml, pretreated with F(ab′)2 epratuzumab 8.1 ±
5.8 pg/ml; p<0.01) or upon combined stimulation
(HD: 227.7 ± 103.8 pg/ml, pretreated with F(ab′)2
epratuzumab 167.0 ± 71.6 pg/ml;p<0.01;patients with
SLE: 238.0 ± 147.1 pg/ml, pretreated with F(ab′)2
epratuzumab 181.5 ± 149.0 pg/ml; p<0.05). Thus, a
clear inhibition was noted for TNF-α production by
activated B cells from HD and patients with SLE under
the influence of F(ab′)2 epratuzumab. This inhibition
was seen after anti-BCR and anti-BCR + CpG activation.
To exclude the possibility that F(ab′)2 epratuzumab has
the ability to engage Fc receptors on B cells and would
lead to an unspecific inhibition of TNF-α and IL-6 secre-
tion after F(ab′)2 epratuzumab incubation, the binding
of an F(ab′)2 epratuzumab isotype control was analyzed
by FC and showed no binding to B cells or other cell
subsets, including T cells, monocytes or natural killer
(NK) cells (data not shown). These data are consistent
with the notion that a specific binding of F(ab′)2 epratu-
zumab to CD22 on B cells was related to the significant
reduction of TNF-α and IL-6 after BCR and anti-BCR +
CpG activation.
In a subsequent analysis, IL-6 production by purified
B cells from HD and patients with SLE was studied
(Fig. 1b). As observed for TNF-α, combined stimulation
induced a synergistic increase of IL-6 production by B
cells from patients with SLE (3397 ± 1353 pg/ml) and
comparably for B cells from HD (anti-BCR + CpG:
3199 ± 1097 pg/ml). The combined stimulation was
again a more potent IL-6 inducer than BCR-cross-
linking alone (anti-BCR; HD: 115.5 ± 80.4 pg/ml; SLE:
153.8 ± 109.8 pg/ml). F(ab′)2 epratuzumab was able to
significantly reduce IL-6 production by anti-BCR alone
F(ab′)2 epratuzumab was able to significantly reduce
IL-6 production by anti-BCR alone (p<0.01) in HD
and SLE cultures, whereas the inhibition by epratuzu-
mab after combined stimulation was not statistically
significant.
We then addressed the influence of epratuzumab on
IL-10 production, a cytokine considered to be an immuno-
regulatory cytokine. Here the combined stimulation was
found to be an important IL-10 inducer compared with
anti-BCR alone (Fig. 1c). However, F(ab′)2 epratuzumab
did not influence the secretion of IL-10 by B cells in any of
the three stimulation conditions tested in both SLE and
HD B cell cultures. There was a trend for B cells from pa-
tients with SLE to produce more IL-10 upon TLR9 and
BCR cross-linking after pretreatment with F(ab′)2 epratu-
zumab (608 ± 420 pg/ml vs. 703 ± 452 pg/ml upon F(ab′)2
epratuzumab), which prompted further studies.
Fig. 1 Targeting of CD22 by epratuzumab influences the secretion
of the proinflammatory cytokines tumor necrosis factor (TNF)-α and
interleukin (IL)-6, but not IL-10, by stimulated B cells. Peripheral blood B
cells were purified from patients with systemic lupus erythematosus (SLE)
(left) and healthy donors (HD) (right), pretreated with (gray squares) or
without F(ab′)2 epratuzumab (open squares) and cultured with
media alone (RPMI) or stimulated with anti–B cell receptor (anti-BCR) or
anti-BCR + CpG. After 2 days of culture, the supernatants were
harvested and tested for TNF-α, IL-6 and IL-10 protein production
using a Bio-Plex Pro™ Human Th17 Cytokine Panel assay. Combined data
from 13 patients with SLE and 9 HD are shown for TNF-α (a), IL-6 (b) and
IL-10 (c) (Mann–Whitney U test; ns = not significant, *p < 0.05, **p < 0.01)
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interleukin-10–producing B cells
IL-10–producing B cells in both humans and mice have
been described as having regulatory functions and to be
impaired in SLE [12–14]. Although epratuzumab did not
substantially affect the secretion of IL-10 by B cells, the
potential capacity of F(ab′)2 epratuzumab to generate
IL-10–producing B cells in vitro was studied by direct
identification of intracellular IL-10 using FC in B cells
after 2 days of BCR cross-linking or combined BCR-
TLR9 stimulation (Fig. 2a). Simultaneous BCR-TLR9
activation induced the highest frequency of IL-10–
producing B cells in HD (9.8 ± 3.3 %), as well as in pa-
tients with SLE (7.4 ± 3.0 %), which was consistent
with the detection of secreted IL-10 (Fig. 1c). There
was no influence of F(ab′)2 epratuzumab on the gener-
ation of IL-10–producing B cells from either patients
with SLE or HD, independent of the stimulation con-
ditions applied (Fig. 2b).
Epratuzumab increases the ratio of interleukin-10 to
proinflammatory cytokines produced by B cells from
patients with systemic lupus erythematosus
To assess whether epratuzumab influences the balance
between IL-10 and the two tested proinflammatory cyto-
kines, the ratios of IL-10 to IL-6 or TNF-α were ana-
lyzed for anti-BCR + CpG stimulation in the individual
donors (Fig. 3).
As a result, the ratio of IL-10 to IL-6 upon anti-BCR +
CpG stimulation was lower in patients with SLE (0.18 ± 0.1)
than in HD (0.21 ± 0.07), but this difference was not
significant. F(ab′)2 epratuzumab influenced the ratio of
IL-10 to IL-6 in patients with SLE (0.24 ± 0.12) and in
HD (0.24 ± 0.06), indicating a change in cytokine bal-
ance in favor of IL-10 as a regulatory cytokine. This dif-
ference between the conditions with or without F(ab′)2
epratuzumab was statistically significant for B cells
from patients with SLE (p<0.01) (Fig. 3a). Similar re-
sults were obtained for the ratio of IL-10 to TNF-α,
whereby F(ab′)2 epratuzumab significantly influenced
the cytokine balance toward IL-10 in B cells from pa-
tients with SLE (p < 0.01) (Fig. 3b). Overall, the ratios
Fig. 2 Epratuzumab does not influence the generation of intracellular interleukin (IL)-10-positive B cells. (a) Frequency of intracellular IL-10+ B cells
after 2 days of peripheral blood mononuclear cell culture of representative healthy donors (HD) or patients with systemic lupus erythematosus, respectively,
without stimulation (RPMI 1640 medium) or stimulated by anti–B cell receptor (anti-BCR) or anti-BCR + CpG using flow cytometry. (b) Comparison of the
frequency of IL-10–producing B cells from 6 patients with SLE and 10 HD without (open squares) and with F(ab′)2 epratuzumab (gray squares) incubation in
response to the indicated stimulations (Mann–Whitney U test)
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the underlying disease activity (according to SLEDAI
score) (data not shown).
Discussion
In this study, we assessed the effect of the anti-CD22
mAb epratuzumab on the production of specific cyto-
kines upon BCR and combined BCR and TLR9 B cell
stimulation in vitro. As a key result, cytokines produced
following BCR activation were TNF-α and IL-6, and
both were substantially reduced upon epratuzumab ex-
posure. Interestingly, the secretion of the immunoregu-
latory cytokine IL-10 in culture supernatants and
intracellular IL-10 production were largely dependent on
TLR9 activation by CpG in both HD and patients with
SLE, and this production was not influenced by epratu-
zumab. Of particular note, immunoregulatory cytokines
appear to be less dependent on BCR activation, but they
have been reported to be intimately involved in regula-
tory circuits of IL-10 and IL-35 production [15].
This study confirms that B cells can be activated by
different pathways, resulting in a distinct modulation ofthe production of certain cytokines. All cytokines stud-
ied were produced at the highest level in the combined
stimulation settings, but it was clear that IL-10 induction
was independent of BCR activation. Whereas enhanced
IL-10 production by cis signaling of Siglec family mem-
bers has been reported for DCs and macrophages [7],
the role of BCR and TLR9 activation on B cells from
controls and patients has not been reported before.
Moreover, reports of the production of IL-10 by B cells
stimulated with different stimuli have been controversial.
Several studies showed an inhibitory effect of anti-IgM
stimulation on IL-10 production by B cells [13], whereas
other studies [16], consistent with our study, showed a
synergistic effect of anti-BCR or anti-BCR + CpG to pro-
duce IL-10. A principal difference that may explain the
different results between these studies is the different
isotypes used to stimulate the BCR, such as IgM only;
IgM and IgG; or IgM, IgG and IgA. Given the inherent
regulatory function of CD22 for BCR activation, the data
we present also support the notion that epratuzumab
has a striking effect on BCR-dependent cytokine produc-
tion (IL-6 and TNF-α) but leaves the TLR9-dependent
Fig. 3 Epratuzumab influences the balance between interleukin (IL)-10
and the proinflammatory cytokines tumor necrosis factor (TNF)-α and
IL-6 secreted by B cells activated by anti–B cell receptor (anti-BCR) +
CpG in patients with systemic lupus erythematosus (SLE). The balance
between IL-10 and proinflammatory cytokines (IL-6 and TNF-α) produced
by B cells from healthy donors (HD) and patients with SLE was evaluated
based on the ratio of IL-10 to IL-6 (a) or IL-10 to TNF-α (b) (Mann–Whitney
U test; **p < 0.01)
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be important to explain the distinct effects when target-
ing CD22 that is closely linked to downstream functions
of BCR activation.
It should be emphasized that the influence of epratu-
zumab on IL-6, TNF-α and IL-10 production was com-
parable between SLE B cells and controls, but that the
ratios of IL-10 to TNF-α and IL-10 to IL-6 were sub-
stantially different in SLE upon BCR-TLR9 stimulation.
Although a potential influence of non-B cells contribut-
ing to the in vitro cytokine production cannot be abso-
lutely excluded, the mean B cell purity of 98.5 ± 2.2 %
with only two samples with 8.2 % and 5.6 % non-B cells
did not likely result in a substantial difference in the in-
fluence of the mAb against CD22, because this bindingis very B cell–specific. Moreover, F(ab′)2 epratuzumab
has been chosen to ensure that the observed effects can
be attributed to a specific CD22 binding and to avoid
potential Fc receptor effects, especially on monocytes,
validated by FC using an F(ab′)2 isotype control. How-
ever, current studies in our laboratory address the com-
prehensive impact of intact epratuzumab on PBMC
cultures, including indirect effects on T cells and mono-
cytes. Because we used negatively selected B cells to
avoid any additional preactivation of B cells by other
purification methods, we believe that the ratios reflect
the situation in individual patients. However, the influ-
ence of the mAb in treated patients needs to be fully
explored.
Conclusions
Epratuzumab targets the BCR coreceptor CD22 and was
found to substantially inhibit the in vitro production of
proinflammatory IL-6 and TNF-α by B cells, likely re-
lated to their close dependence on BCR signaling [6]. In
contrast, IL-10 production, reportedly less dependent on
BCR activation, was not substantially influenced by epra-
tuzumab. These data suggest that epratuzumab alters
the balance between the production of proinflammatory
cytokines (TNF-α, IL-6) and the regulatory cytokine
IL-10 as another B cell effector mechanism. The findings
provide further evidence that epratuzumab can affect
downstream BCR functions such as particular cytokines
produced by B cells.
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